Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) EBIT

Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) (PBAXU) currently reports a EBIT of $-18M as of March 2026. That compares with $-23M in the prior-year period — up 21.6% year over year. That is above the sector sector average of $-77M. Use the charts on this page to explore Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s EBIT history and peer comparisons.

Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s EBIT increased from $-23M to $-18M — a 21.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s EBIT of $-18M is higher than the its sector sector average of $-77M. That is roughly 76.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) reported $-18M in EBIT as of March 2026. That compares with $-23M in the prior-year period — up 21.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-18M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-77M. From there, open related valuation or income-statement pages for Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War), and consider following PBAXU for alerts when major investors trade the stock.